Skip to content

Depression: all studies

Page 385 of 1,036: studies 3,841 to 3,850 of 10,358, newest first. Back to the depression overview

Research

Effects of virtual reality guided meditation in older adults: the protocol of a pilot randomized controlled trial.

Frontiers in Psychology 2023 Karin Cinalioglu, Paola Lavín, Magnus Bein et al. 21 citations

Virtual reality (VR) based meditation has been shown to help increase relaxation and decrease anxiety and depression in younger adults. However, this has not been studied in Randomized Controlled Trials (RCT) in the older adult population. The aim of this RCT is to assess the feasibility and acceptability of a VR-guided meditation intervention for community-dwelling older adults and its effect...

Do yoga and meditation moderate the relationship between negative life events and depressive symptoms? Analysis of a national cross-sectional survey of Australian women.

Frontiers in Psychology 2023 Romy Lauche, Dennis Anheyer, Lisa A Uebelacker et al.

This study aims to examine the role of yoga/meditation in the relationship between negative life events, stress and depression. The Australian Longitudinal Study on Women's Health (ALSWH) surveyed 7,186 women aged 36-43 years (mean age 39.2 years; 57.2% university degree) in 2015. Mediation and moderation analyses were conducted to examine whether yoga/meditation practice moderated those...

Evaluating passive physiological data collection during Spravato treatment.

Frontiers in Digital Health 2023 Todd M Solomon, Matus Hajduk, Martin Majernik et al. 1 citation

Spravato and other drugs with consciousness-altering effects show significant promise for treating various mental health disorders. However, the effects of these treatments necessitate a substantial degree of patient monitoring which can be burdensome to healthcare providers and may make these treatments less accessible for prospective patients. Continuous passive monitoring via digital devices...

Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.

Psychopharmacology 2023 Juliet Meccia, Joëlle Lopez, Rosemary C. Bagot 14 citations

Interest in the therapeutic potential of serotonergic psychedelic compounds including psilocybin has surged in recent years. While human clinical research suggests psilocybin holds promise as a rapid and long-lasting antidepressant, little is known about how its acute mechanisms of action mediate enduring alterations in cognition and behavior. Human neuroimaging studies point to both acute and...

Is psilocybin an effective antidepressant and what is its Mechanism of action?

Cell Reports Medicine 2023 J. John Mann 7 citations

Goodwin et al.1 report a single 25 mg dose of psilocybin has an antidepressant effect short-term in medication-resistant depression. Unanswered questions include drug blood level as a guide to dose, psychedelic effects relationship to antidepressant benefit, and potential suicide risk of psilocybin.

Therapeutic Effects of Ceremonial Ayahuasca Use for Methamphetamine Use Disorders and Other Mental Health Challenges: Case Studies in an Indigenous Community in Sonora, Mexico.

Journal of Psychoactive Drugs 2023 Anja Loizaga-Velder, Cecile Giovannetti, Ricardo Campoy Gomez et al. 9 citations

This paper describes three case studies from an outpatient intercultural therapeutic program founded and run by Yaqui health professionals and traditional healers to serve members of the Yaqui tribe residing in Sonora, Mexico. This pilot therapeutic program has been designed specifically for Indigenous individuals, incorporating the ceremonial use of naturally derived psychedelics in addressing...

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.

Frontiers in Psychiatry 2023 Ellen James, David Erritzøe, Tiffanie Benway et al. 16 citations

Due to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) in the treatment of major depressive disorder (MDD). The aim of Part A of this study was to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) profile of escalating doses of SPL026 (DMT fumarate)...

(+)-Catharanthine and (-)-18-methoxycoronaridine induce antidepressant-like activity in mice by differently recruiting serotonergic and norepinephrinergic neurotransmission.

European Journal of Pharmacology December 19, 2022 Hugo R Arias, Philippe De Deurwaerdère, Ali El-Kasaby et al.

The antidepressant-like activity of (+)-catharanthine and (-)-18-methoxycoronaridine [(-)-18-MC] was studied in male and female mice using forced swim (FST) and tail suspension tests (TST). The underlying molecular mechanism was assessed by electrophysiological, radioligand, and functional experiments. The FST results showed that acute administration (40 mg/kg) of (+)-catharanthine or (-)-18-MC...

Nightmares and psychiatric symptoms: A systematic review of longitudinal, experimental, and clinical trial studies.

Clinical Psychology Review December 17, 2022 Bryony Sheaves, Stephanie Rek, Daniel K. Freeman

Nightmares occur across a wide range of psychiatric disorders, but outside of PTSD presentations are infrequently considered a treatment priority. We aimed to assess evidence for a contributory causal role of nightmares to the occurrence of psychiatric disorders, and vice versa. A systematic review was conducted of longitudinal, experimental, and clinical trial studies. Twenty-four...

Moderators of ayahuasca’s biological antidepressant action

Frontiers in Psychiatry December 5, 2022 Geovan Menezes de Sousa, Vagner Deuel de Oliveira Tavares, Ana Cecília de Menezes Galvão et al. 14 citations

Introduction The understanding of biological responses to psychedelics with antidepressant potential is imperative. Here we report how a set of acute parameters, namely emotional (depressive symptoms), cognitive (psychedelic experience), and physiological (salivary cortisol), recorded during an ayahuasca dosing session, modulated serum brain-derived neurotrophic factor (BDNF), serum cortisol...

DOI: 10.3389/fpsyt.2022.1033816 (opens in new tab) Cortisol Inflammation Psychedelics hallucinogens Entheogens +7